Teresa Contreras

Salamanca, CL, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Reply.

Reply.

Journal: The Journal of allergy and clinical immunology
Published: February 24, 2026

A critical analysis of the IMWG multiple myeloma complete response criterion in the era of mass spectrometry.

A critical analysis of the IMWG multiple myeloma complete response criterion in the era of mass spectrometry.

Journal: HemaSphere
Published: August 21, 2025

Immunologic biomarkers of noninfectious complications and overall survival in common variable immunodeficiency.

Immunologic biomarkers of noninfectious complications and overall survival in common variable immunodeficiency.

Journal: The Journal of allergy and clinical immunology
Published: May 13, 2025

Normal Residual Lymphoid Cell Populations in Blood as Surrogate Biomarker of the Leukemia Cell Kinetics in CLL BinetA/Rai 0.

Normal Residual Lymphoid Cell Populations in Blood as Surrogate Biomarker of the Leukemia Cell Kinetics in CLL BinetA/Rai 0.

Journal: Cancers
Published: October 31, 2024

Title Not Found

Title Not Found

Journal: Advances in laboratory medicine
Published: June 28, 2024

Mass spectrometry in clinical protein laboratories.

Mass spectrometry in clinical protein laboratories.

Journal: Advances in laboratory medicine
Published: May 21, 2024

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial.

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial.

Journal: Haematologica
Published: April 23, 2024

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma.

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma.

Journal: Blood
Published: April 16, 2024

Mass Spectrometry as Alternative Method to Identify and Monitor Non-Secretory Progressive Disease in Patients with Multiple Myeloma.

Mass Spectrometry as Alternative Method to Identify and Monitor Non-Secretory Progressive Disease in Patients with Multiple Myeloma.

Journal: Biomedicines
Published: February 26, 2024

Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia.

Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia.

Journal: Leukemia
Published: January 24, 2018

Host virus and pneumococcus-specific immune responses in high-count monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia: implications for disease progression.

Host virus and pneumococcus-specific immune responses in high-count monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia: implications for disease progression.

Journal: Haematologica
Published: October 26, 2016

Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.

Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.

Journal: Blood
Published: April 09, 2015
Showing 1-12 of 12

Last Updated: 09/26/2026